Literature DB >> 21309114

Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder.

Dennis C Choi1, Barbara O Rothbaum, Maryrose Gerardi, Kerry J Ressler.   

Abstract

Improved efficacy in the treatment of posttraumatic stress disorder (PTSD) and other anxiety disorders is urgently needed. Traditional anxiety treatments of hypnosis and psychodynamic therapy may be of some help, but uncontrolled studies lead to inconclusive results on the efficacy of these treatment techniques. There is a larger literature supporting the efficacy of cognitive-behavioral procedures with PTSD, including prolonged exposure therapy, eye movement desensitization and reprocessing, and anxiety management techniques. The cutting-edge technology of virtual reality-based exposure therapy for PTSD is particularly exciting. To further build on effective psychosocial treatments, current pharmacological augmentation approaches to emotional learning are being combined with psychotherapy. In particular, D-cycloserine, a partial NMDA agonist, has shown to be effective in facilitating the exposure/extinction therapy to improve the efficacy of treating anxiety disorders, and may guide the way for new pharmacological enhancements of behavioral therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21309114     DOI: 10.1007/7854_2009_10

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  16 in total

Review 1.  Fear extinction and BDNF: translating animal models of PTSD to the clinic.

Authors:  R Andero; K J Ressler
Journal:  Genes Brain Behav       Date:  2012-05-11       Impact factor: 3.449

2.  Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.

Authors:  Neal R Swerdlow; Savita G Bhakta; Gregory A Light
Journal:  Schizophr Res       Date:  2018-04-05       Impact factor: 4.939

3.  Increased prefrontal cortex neurogranin enhances plasticity and extinction learning.

Authors:  Ling Zhong; Joshua Brown; Audra Kramer; Kanwardeep Kaleka; Amber Petersen; Jamie N Krueger; Matthew Florence; Matthew J Muelbl; Michelle Battle; Geoffrey G Murphy; Christopher M Olsen; Nashaat Z Gerges
Journal:  J Neurosci       Date:  2015-05-13       Impact factor: 6.167

4.  From antipsychotic to anti-schizophrenia drugs: role of animal models.

Authors:  Mark A Geyer; Berend Olivier; Marian Joëls; René S Kahn
Journal:  Trends Pharmacol Sci       Date:  2012-07-16       Impact factor: 14.819

Review 5.  Animal models of fear relapse.

Authors:  Travis D Goode; Stephen Maren
Journal:  ILAR J       Date:  2014

Review 6.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

Review 7.  Pharmacological secondary prevention of PTSD in youth: challenges and opportunities for advancement.

Authors:  Matthew A Maccani; Douglas L Delahanty; Nicole R Nugent; Steven J Berkowitz
Journal:  J Trauma Stress       Date:  2012-10

Review 8.  Targeting memory processes with drugs to prevent or cure PTSD.

Authors:  Christopher K Cain; George D Maynard; John H Kehne
Journal:  Expert Opin Investig Drugs       Date:  2012-07-27       Impact factor: 6.206

9.  Enhancing Endocannabinoid Neurotransmission Augments The Efficacy of Extinction Training and Ameliorates Traumatic Stress-Induced Behavioral Alterations in Rats.

Authors:  Maria Morena; Andrea Berardi; Paola Colucci; Maura Palmery; Viviana Trezza; Matthew N Hill; Patrizia Campolongo
Journal:  Neuropsychopharmacology       Date:  2017-12-21       Impact factor: 7.853

10.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.